Novavax, Inc.
NMS: NVAXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Novavax, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get NVAX Z-Score →About Novavax, Inc.
Healthcare
Biotechnology
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
📊 Fundamental Analysis
Novavax, Inc. demonstrates exceptional profitability, with a profit margin of 39.2%.
The company recently reported 66.6% revenue growth, which is well above average for the Healthcare sector.
At a current price of $8.12, NVAX currently sits at the 38th percentile of its 52-week range (Range: $5.80 - $11.97).
💰 Valuation Insight
NVAX trades at a 87.4% discount (PE: 3.15), which may represent a value opportunity given the sector average of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
✅
Revenue Growth
Excellent
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$1.32B
Trailing P/E
3.15
Forward P/E
-8.01
Beta (5Y)
2.65
52W High
$11.97
52W Low
$5.80
Avg Volume
5.06M
Day High
Day Low